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Background: Seventeen 1,4-dihydroquinoline-3-carboxamide and 1,4-dihydroquinoline-3-carbohydrazide derivatives
of gatifloxacin have been prepared with a facile one step synthesis aiming to improve antibacterial, antifungal and
immunological activities. The methodology allows the introduction of a variety of substituents such as amines,
alcohol, phenol, amides and alkyl halides into the core structure of gatifloxacin.
Results: The analog N-(3-aminophenyl)-1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide has been identified as a potentially excellent anti-inflammatory agent, which
exhibited highly potent effects on the oxidative burst activity of whole blood phagocytes (IC50 <12.5 μg mL-1),
neutrophils (IC50 <0.1 μg mL-1) and macrophages phagocytes (IC50 <3.1 μg mL-1) as well as potent T-cell proliferation
inhibitory effect (IC50 3.7 μg mL-1) while having comparable antibacterial activity to gatifloxacin. Another analog,
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carbohydrazide has
tremendous T-cell proliferation inhibitory effect IC50 <3.1 μg mL-1 as compared to prednisolone, whereas, 3,5-
dihydroxyphenyl1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate
and 2-hydroxyphenyl-1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate envision good inhibitory activity on T-cells proliferation (IC50 6.8 & 8.8 μg mL-1 respectively).
Conclusions: The structural modification at carboxylic group has resulted in improved anti-inflammatory activities with
comparable antibacterial activity to gatifloxacin. We believe that C3 structural modifications of gatifloxacin are definitely
important in bringing major immunomodulatory changes in these compounds.
Keywords: Gatifloxacin analogues, Oxidative burst response, T-cell proliferation, Fluoroquinolone NSAIDSBackground
An infection is a pathological process whereby an ex-
ogenous agent (fungus, bacterium or virus) invades the
body causing some form of injurious dysfunction. Upon
infection of bacteria, inflammatory cytokines (such as
TNF-α) are produced from macrophages and can lead to
various conditions such as allergic diseases, autoimmune
diseases and inflammatory diseases [1], such as cystic
fibrosis characterized by chronic neutrophilic inflamma-
tion [2,3]. Such diseases are required to be treated with* Correspondence: msarayne@gmail.com
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reproduction in any medium, provided the orimmune system-harmless anti-inflammatory agents and
antimicrobial agents in combination. Fluoroquinolones
have long been used as antimicrobial therapy in respira-
tory, urinary, GI and sexual infections [4]. Several stud-
ies have shown that new fluoroquinolones also possess
immunomodulatory properties beyond their antimicro-
bial effects [5]. Gatifloxacin sesquihydrate, a synthetic
broad-spectrum antimicrobial fluoroquinolone [6-9], has
also an inhibition effect on the production of inflamma-
tory cytokines by macrophages, monocytes or periph-
eral lymphocytes and particularly suppresses bacterial
infection-induced inflammation [10,11]. On the basis of
anti-inflammatory activity of gatifloxacin, our initialral Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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structural modification of gatifloxacin in an anticipation
of preservation of the antibacterial activity with en-
hancement of its anti-inflammatory activity.
It is established that N1, C2–H, C3-carboxylic acid, C4-
carbonyl, C6-F, and C7-piperazine are essential or benefi-
cial for the antibacterial activity of fluoroquinolones
[12,13]. Modification or elimination of these groups would
also give us the valuable structural information for the im-
provement of anti-inflammatory effects. So far only few
lipophilic gatifloxacin analogues are reported in literature
[14,15]. Dharmarajan and coworkers prepared sixteen
lipophilic N-substituted piperazinyl Mannich bases of gati-
floxacin [14]. Similarly Mauro et al., [12] synthesized lipo-
philic gatifloxacin derivatives and evaluated for their anti-
tubercular activity, all analogs proved to be less potent
than parent drug.
We prepared seventeen different derivatives of gati-
floxacin with a facile, one step synthesis with high yield
aiming to improve antibacterial, antifungal and immuno-
logical activities. Our methodology allows the introduc-
tion of a variety of substituents such as amines, alcohol,
phenol, amides and alkyl halides into the core structure
of gatifloxacin. The structural modification of gatifloxacin
and the rationale for the modification is summarized in
Schemes 1 & 2. 1,4-dihydroquinoline-3-carboxamide
(4–12) and 1-4-dihydroquinoline-3-carbohydrazine (13–14)
analogues of gatifloxacin, formation proceeds via the
usual pathway of nucleophilic substitution (Scheme 1).
Simplest Fischer method was adopted for the formation
of 1,4- dihydroquinoline-3-carboylate derivatives (15–20),
an example of acid catalyzed esterification (Scheme 2).
Our initial success to identify the quinolone based anti-
inflammatory agent 7, envisions the potent oxidative burst
activity on the whole blood phagocytes, neutrophils and
macrophages and has an inhibition effect on T-cell prolif-















Reflux 4hr at 60oC
Gatifloxacin Gatifloxacin
Where,
4 R = C6H4.CH3, 5 R = C10H8, 6 R = C6H5, 7 R = C6
COC6H5, 11  R = C=SCH3, 12 R = C12H8 13 R =NH2
Scheme 1 Synthesis of 1, 4 dihydroquinoline-3-carboxamide (4–12) aResults and discussion
Structural characterization
The absorption intensity of the carbonyl group was
decreased and shifted towards right near 1629–1608 cm–1
in all the 3-carboxamide derivatives. No peak was observed
for carboxylic OH absorption in the FTIR spectra of these
derivatives but a distinct strong and un-obscured NH
stretch was observed at 3200 cm-1. It was observed that
the 1H NMR spectra of 4–12 derivatives showed a broad
singlet of NH of amide at 7.88-5.68 ppm while did not
show peak for acidic proton at 12 ppm [16,17]. All these
facts clearly indicate that carboxylic site reacted with the
selected amines forming amides. FTIR spectra of 15–20
showed the characteristic strong absorption band arising
from C=O and C-O; the intensive C=O stretching vibra-
tion occurs at higher frequencies 1709–1735 cm-1 than
C=O of ketone (present in parent drug) due to electron
withdrawing effect (inductive effect) indicating formation
of ester linkage and successfulness of coupling reaction.
The 1HNMR spectra of all derivatives do not show signal
at 12 ppm, confirming that the carboxylic group of gati-
floxacin was utilized in reaction with phenols derivatives.
FTIR spectra of 16 and 17 showed C=O stretching at
1729 cm-1, the 1HNMR spectra as it do not show any
signal for NH of amide and a triplet signal of additional
aromatic proton attached to C-18 at 7.01 ppm and multi-
plet signals of protons attached to C −19, 21 at 6.16-6.10
indicate that –OH group of aminophenol utilized in for-
mation of these compound instead of amino group.
Immunomodulatory effects
Many clinical disorders are associated with immune sys-
tem. The human immune system comprises of innate
and specific immunity. The innate immunity involves a
range of specialized cells such as neutrophils, eosinophils
and monocyte/macrophages in blood and in many body
tissues while the T lymphocytes and B-lymphocytes are

















Reflux 2-3 hr at 60oC
 ester derivative Gatifloxacin carboxamide or 
carohydrazide derivatives
H4NH2, 8 R = CONH2, 9 R = C6H4COOH, 10 R = 
 and 14 R = NHC6H5.




















Gatifloxacin Gatifloxacin ester derivative
Where, 
15  R = C6H5,   16  R = C6H4NH2 , 17 R = C6H4NH2 , 18   R = C6H4OH, 19  R= C6H3(OH)2, and 
20  R = C6H4OH
Scheme 2 Synthesis of 1,4 dihydroquinoline-3-carboxylate derivatives (15–20).
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http://www.journal.chemistrycentral.com/content/7/1/6The NADPH oxidase is a multiunit enzyme that is respon-
sible for producing superoxide anion (utilizing oxygen)
which is quickly converted to hydrogen peroxide and hy-
droxyl radicals [19] as an antimicrobial agents. Abnormal-
ities in the constituent peptides of the NADPH oxidase
enzyme system lead to dysfunctions characteristic of
chronic granulomatous disease (CGD). Neutrophils from
CGD defected patients are unable to produce significant
oxidative burst following activation. The oxidative burst is
impaired in disorders related to innate immunity like in
transplant, AIDS patients and in infectious diseases; onTable 1 Screening of gatifloxacin and its derivatives for chem
Compound RLU Reading
concentration (μg mL-1) 100 50 12.5
4 1859.3 1831.4 1540.9
5 74.7 127.7 378.3
6 172.8 435.2 873.8
7 −1.7 −1.1 5
8 200.5 402.6 905.1
9 777.9 939.1 945.2
10 306.9 736.1 1520
11 823.7 958.1 1129
12 1028.5 970.8 1334
13 503.6 705.5 1060
14 74.3 219.6 663.1
15 109.6 222.1 444.6
16 15.7 23.1 71.7
17 20.5 48.3 226.7
18 637.3 879.9 1199.9
19 379.6 676.6 1047.4
20 99.5 143.6 389.8
Gatifloxacin 162.4 360.6 852.1the other hand it is highly elevated in inflammatory disor-
ders [20].
So as to test the immunomodulatory effect of gatifloxa-
cin and its seventeen analogues, we investigated their
effect on the oxidative burst ROS production activity of
whole blood (Table 1 and Figure 1), isolated neutrophils
and macrophages phagocytes (Figure 2) and the inhibitory
effects on the proliferation of T cells (Table 2 & Figure 3)
along with toxicity studies (Figure 4).
ROS can be monitored and quantified by a luminol
enhanced chemiluminescence technique. The luminol iniluminescence activity using whole blood
Inhibition% IC50 ± S.D
100 50 12.5
−75.16 −72.53 −45.16 >100
92.96 87.97 64.36 <12.5
83.72 59 17.68 39.3 ± 12.3
100.16 100.1 99.53 <12.5
81.11 62.08 14.73 34.6 ± 9.8
26.72 11.53 10.96 >100
71.09 30.66 −43.18 69.6 ± 1.9
22.41 9.74 −6.39 >100
3.11 8.55 −25.72 >100
52.56 33.54 0.13 90.7 ± 13.2
93.01 79.31 37.53 21.5 ± 6.7
89.68 79.08 58.12 <12.5
98.52 97.82 93.25 <12.5
98.07 95.45 78.64 <12.5
39.96 17.11 −13.03 >100
64.24 36.26 1.33 73.6 ± 0.4
90.62 86.47 63.28 <12.5































Figure 1 The Immunomodulatory effects of gatifloxacin (GTX) and its analog compounds on oxidative burst response using whole
blood cells. Each bar represents a mean triplicate reading. +ve = Cells + Zymosan, -ve = Cells without zymosan.
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http://www.journal.chemistrycentral.com/content/7/1/6a probe detects intracellular ROS after cells activation
with serum opsonized zymosan [19,21]. The preliminary
screening results of whole blood phagocytosis showed
compounds 5, 7, 15, 16, 17 and 20 exhibiting highly po-
tent inhibitory effects on oxidative burst response at all
concentrations while gatifloxacin exerted a moderate ac-
tivity with IC50 31 μg mL
















































Figure 2 The Immunomodulatory effects of quinolone derivatives on
mouse peritoneal macrophages (B). Each bar represents a mean of tripli
zymosan activation. The solid bar [black] represents the activated control gthese compounds were 64.4, 99.5, 58.1, 93.2, 78.6 and
62.9% respectively at 12.5 μg mL-1 concentration
(Table 1). In another set of experiment the above men-
tioned six compounds again demonstrated an extremely
potent inhibition on the isolated neutrophils with IC50,
<0.1, <0.1, 1.7, 0.2, 2.4 and 0.2 μg mL-1 respectively










oxidative burst response using isolated neutrophils (A) and
cate reading after 30-minute incubation and then serum opsonized
roup cells [Neutrophiles/Macrophages].
Table 2 Screening of gatifloxacin and its synthesized derivatives using whole blood for their immune modulating
inhibitory properties
Compound CPM Reading Inhibition% IC50 ± SD
Conc (μg/mL) 50 12.5 3.12 50 12.5 3.12
4 18538.3 25229.4 29076.6 45.86 26.32 15.09 >50
5 476.3 33339.6 33370.4 97.6 −70.7 −70.9 24 ± 0.5
6 10678.5 22012.4 30970.5 45.3 −12.7 −58.6 23.9 ± 9
7 286.6 4554.4 18804.47 99.16 86.7 45.09 3.7 ± 0.1
8 6988.7 46099.7 40114.8 64.2 −136 −105.4 35.5 ± 0.4
9 16087.9 40831.9 40689 17.6 −109.1 −108.3 43.5
10 40893.6 46979.2 45283.2 −109.4 −140.5 −131.8 >50
11 13122.8 33977.4 35965.9 32.8 −74 −84.1 37.5 ±1.5
12 13691.3 41857.5 39169.8 30 −114.3 −100.5 40.7 ± 0.5
13 42380 70222.1 52258.6 −23.7 −105.05 −52.59 >50
14 257.3 2182.5 10766.9 98.7 88.8 44.9 <3.12
15 7470.6 29308.1 32117.4 61.8 −50.1 −64.4 27 ± 2.6
16 34845.8 43188.6 38111.9 −78.4 −121.1 −95.1 >50
17 10892.5 31624.6 35370.22 44.2 −61.9 −81.1 33.0 ± 0.8
18 27012.8 30291.9 30529.1 −38.3 −55.1 −56.3 >50
19 117 14599.9 22362.3 99.4 25.2 −14.5 6.8 ± 0.3
20 2932.7 14825.1 22921.5 85 24 −17.4 8.8 ± 2.8
Gatifloxacin 24450.9 38657.7 33427.3 −25.2 −97.9 −71.1 > 50
Standard 654.2 1906.8 1945.7 98.089 94.432 94.318 < 3.12
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http://www.journal.chemistrycentral.com/content/7/1/6envisaged outstanding activity against macrophages and
phagocytes (Figure 2B), compound 7 and 16 having IC50
lower than 3.1 μg mL-1 while compound 15 and 17 had
IC50 8.5 and 12.9 μg mL
-1 respectively (Table 3).
The results of chemiluminescence assay and structures
of these compounds suggest that amide and ester deriva-
tives of gatifloxacin with a suitably substituted exocyclic
phenyl ring posses potent anti-inflammatory activities.























Figure 3 The modulatory effects of gatifloxacin (GTX) and its analog
compared with prednisolone (Std). Each bar represents a mean triplicateability to be protonated at physiological (pH 7.4) to form
ionic, hydrogen, dipole-ionic or dipole–dipole bonding
with target molecule which strengthen the pharmaco-
dynamics properties [22]. The compounds having exo-
cyclic substituted phenylenamine ring at C-3 position
of the quinolone core showed varying degrees of activ-
ities as in case of compounds 5, 7, 15, 16, 17 and 20.
The most active compounds of the series were 7 and




compounds (4–20) on mitogen activated T-cell proliferation
























Figure 4 Represents toxic effect of compounds 5, 7, 14, 19 and 20 on PHA activated T-cells proliferation compared to prednisolone.
T-cells were incubated with compounds/prednisolone for 24 hrs then washed and activated for further 72 hrs with PHA. The bars represent the
level of T-cells proliferation compared to controls [cells + PHA (+ve) and cells without PHA (−ve)]. Each bar represents a mean of triplicate
reading.
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quirement, described above. However the difference in the
activity between the compound 7 and 16 might be due to
the presence of additional amino group in compound 7
that afford supplementary binding site in drug molecule.
Compounds 16 and 17 are position isomers and 16 is
more potent than 17 which demonstrate m-amino at
phenyl group turn out to exhibit more potent activity
than o-amino group. The results suggest that the ability
of compound to form the phenylamine radical and the
stability of this derived radical are important in the
anti-inflammatory activities via neutralization of harm-
ful radicals.
Furthermore we tested gatifloxacin and its seventeen
derivatives for anti-proliferation effect by measuring the
inhibition of phytohemagglutinin (PHA) induced T- cell
proliferation by determining radioactive thymidine in-
corporation and prednisolone was used as standard
drug. Results shown in Table 3 & Figure 3 evidently
point out that gatifloxacin itself has no suppression
effects on T-cells. However compounds 7, 14, 19 and
compound 20 exert potent antiproliferative activities. ATable 3 The comparative IC50 (μgmL
-1) effect of
gatifloxacin and test compounds on oxidative burst of
whole blood, isolated PMNs, and mouse peritoneal
macrophages
Compound Whole blood PMNs Macrophages
Gatifloxacin > 30 > 30 > 30
5 <<12.5 <<0.1 24.5 ± 5.6
7 <<12.5 <0.1 <3.1
15 <12.5 1.7 ± 0.6 8.5 ± 0.6
16 <<12.5 0.2 ± 0.1 7.6± 0.6
17 <<12.5 2.4 ± 1.0 12.9 ± 0.2
20 <12.5 0.2 ± 0.1 –dose as low as 3.1 μg/mL of compound 14 caused re-
markable reduction (68.6%) in T-cell proliferation com-
pared to control. The IC50 value was < 3.1 μg mL
-1 and
this activity is not due to toxic effects as 92.9% cells are
found alive when tested for toxicity whereas, in case of
prednisolone only 34.3% cells remained alive. Compound
7 also envisions its good anti-proliferative T-cell together
with excellent ROS oxidative burst effect. It had IC50
value 3.7 μg mL-1 and 80% cells remained alive in tox-
icity evaluation assay at 3.1 μg mL-1 concentration
(Figure 4). Compound 7 and 14 had similar beneficial
antiproliferative activity as compared to prednisolone
(IC50 value < 3.12 μg mL
-1) but with improved safety pro-
file (Figure 4). Therefore the compound 7 and 14 proved
as an excellent quinolone based anti-inflammatory or im-
munosuppressive activity.
Compounds 19 and 20, 1,4-dihydroquinoline-3-carboylate
analogs, showed significant inhibitory effect on T-cell
proliferation with IC50 6.8 μg mL
-1 and 8.8 μg mL-1 re-
spectively (Table 2). The most important is that com-
pound 20 reduced 91.4% T cell proliferation, similar to
prednisolone 98.1%. Nevertheless the inhibitory activity
of compound 20 is not due to toxic effect since 62.6%
cells were found alive whereas in case of predinosolne
only 6.9% cells remain alive at 50 μg mL-1 (Figure 4).
Compound 19 exert 57.4% of immunosuppressive activity
without any toxic effect at 12.5 μg mL-1 concentration.
The results suggest that quinolone based compounds that
have exocyclic suitable substituted phenyl ring possess
immunosuppressive activity especially when there is phe-
nylhyrazine or phenylenediamine attached to C-3 of quin-
olone ring envision superb activity with less cytotoxic
effect and compound with extra hydroxyl at ortho pos-
ition of exocyclic phenyl produce significant activity with
no toxic effect. However both compounds do not exert
any significant effect on oxidative burst of phagocytes.
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resulted in improved anti-inflammatory activities with
comparable antibacterial activity to gatifloxacin. There-
fore we believe that the C3 structural modifications of
gatifloxacin are definitely important in bringing major
immunomodulatory changes in these compounds.
Experimental
Chemistry
All reagents were of analytical grade purchased from
Merck (Germany). Gatifloxacin (98.67%) was gratis from
Barrett Hodgson Pakistan. IR and 1H-NMR spectra were
recorded on Prestige-21 Shimadzu FTIR (KBr) and Bru-
ker AMX (400 MHz), respectively. Chemical shifts are
reported in ppm using tetramethylsilane (TMS) as an in-
ternal standard. However 13C NMR were not performed
as gatifloxacin is a well established molecule and struc-
tural changes of derivatives were confirmed by IR, 1H-
NMR and by mass spectra. The mass spectra were
recorded on MAT312 Mass spectrometer (Jeol, Tokyo,
Japan) operating at 70 eV by electron ionization technique
(EI-MS). Zymosan A was purchased from Fluka Biochem-
ika (Switzerland), HBSS– and HBSS++ were obtained from
Sigma-Aldrich (Steinheim, Germany), Luminol from Alfa
Aesar (Karlsruhe, Germany), FBS (Fetal Bovine Serum)
purchased from PAA Laboratories GmbH (Pasching,
Austria), RPMI-1640 (Roswell Park Memorial Institute)
from MP biomedicals (USA), Lyophilized PHA (Phyto-
hemagglutinin) purchased from Sigma–Aldrich (St. Louis,
USA). Chemiluminescence and T-Cell proliferation assay
were performed using Luminoskan EL, RT, RS from Lab-
systems (Helsinki, Finland), LS 6500 β-Scintillation Coun-
ter from Beckman Coulter (Fullerton, CA, USA) and Cell
Harvester System purchased from INOTECH (Dottikon,
Switzerland).
General procedure of synthesis
The carboxamide and carbohydrazide derivatives were
prepared as summarized in Scheme 1. 2.48 mmole solu-
tion of gatifloxacin in methanol was acidified by adding
1–2 drops of concentrated sulfuric acid and heated at
60°C refluxed for about 4 hours till the consumption of
gatifloxacin in ester formation (monitored by TLC). The
ester was subjected to nucleophilic attack by adding 3
mmole methanolic solutions of aromatic amines or hy-
drazine respectively with continuous stirring to generate
corresponding carboxamides or carbohydrazides. The re-
action was processed for about 2–3 hours till comple-
tion, indicated by TLC [23]. The caroboxylates were
prepared by stirring the mixture of gatifloxacin (1 gm,
2.48 mmole) and methanolic solution of alcohol or phe-
nol derivative (3 mmole) in acidic medium at 60°C
under reflux (Scheme 2). The mixture was cooled to
room temperature and excess solvent was removedunder reduced pressure; the residue was suspended in
water and extracted with ethyl acetate (8 mL x 3). The
organic phase was dried over Na2SO4 (anhydrous),
filtered and evaporated to dryness then washed with
chloroform and re-crystallized from ethanol-chloroform
(3:2) mixture till pure compounds were obtained
(ensured by TLC and constant melting point).
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-
4-oxo-N-p-tolyl-1,4-dihydroquinoline-3-carboxamide [4]
Yield 78% , m.p. 117°C, UV nm (ε): 221.5 nm (27144),
292.5 nm (12158), 324.5 nm (4590), IR (KBr) νmax: 3497,
2960–2852, 1625, 1521, 1443, 1352, 1182, 1043 cm-1, 1H
NMR (MeOD, 400 MHz) δ: 0.94-1.23 (m, 4H, cyclopro-
pane), 1.45-1.47(d, 3H, J = 5.92 CH3 of piperazine ring),
1.87-2.25 & 3.46-3.48, m, 7H of piperazine ring), 3.65
(s, 3H, OCH3), 3.93-3.95 (m, 1H of cyclopropane), 5.68
or 6.84 (bs, NH of amide), 7.05-7.20 & 7.36-7.629 (m, 4H
aromatic), 7.2 (s, MeOD), 7.87-7.89 (d, 1H, J = 11.68), 8.80
(s, 1H). Mass (m/z,%): 464.5(M+ 4.6), 409(2.9), 390(3.5),
375(38.1), 319(100), 288(6.3), 245(9), 172(63.5), 77(8)
calculated for C26H29FN4O3: C, 67.24; H, 6.25; N, 12.06.




Yield 71% , m.p. 110°C, UV nm (ε): 214 (73915), 258
(16253), 290 (37988), 324 (12588), IR (KBr) νmax: 3470–
3350, 3258, 3053, 2857, 2352–2343, 1625, 1579–69,
1456–1442, 1392 cm-1, 1H NMR (MeOD, 400 MHz) δ:
0.87-0.98 & 1.08-1.30 (m, 4H cyclopropane), 1.37-1.39
(d, 3H, J = 8), 1.53 & 2.86-3.46 (m, 7H, of piperazine
ring), 3.74 (s, OCH3), 3.97-4.02 (m, 1H, cyclopropane),
6.70-6.75 (dd, 1H, aromatic C31), 7.23 (s, MeOD), 7.26-
7.83 (m, 8H, aromatic), 7.88 (d, 1H, NH), 8.79 (s, 1H,
aromatic C2). Mass (m/z,%): 500(M+ 0.89), 444(9), 56
(15.69), 430(1.3), 70(17.02), 375(28.6), 346(2.8), 319(100),
176(4.1), 143(72), 149(5.85) calculated for C29H29FN4O3: C,
69.6; H, 5.8; N, 11.2. Found: C, 69.53; H, 5.78; N, 11.19.
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-
4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide [6]
Yield 81% , m.p. 198°C, UV nm (ε): 213 (32777), 262
(24724), 313 (23829.39), IR (KBr) νmax: 3347, 3291, 3086,
2930, 2860, 2356, 1608, 1550, 1516, 1447, 1245, 1117,
1059 cm-1, 1H NMR (MeOD, 400 MHz) δ: 0.86-0.98 &
1.06-1.205 (m, 4H cyclopropane), 1.42-1.396 (d, 3H, J = 8),
2.03 (s, 1H, NH), 2.92-3.50 (m, 7H, of piperazine ring),
3.75 (s, OCH3), 4.00 (m, 1H, cyclopropane), 6.229 (s, 1H,
NH), 7.047-7.11 (m, 1H, aromatic C30), 7.23 (s, MeOD),
7.29-7.36 (m, 2H, aromatic C29,31), 7.83-7.87 (d, 1H, aro-
matic C5, J =12.17 ), 8.376-8.395 (m, 2H, C28,32 ), 8.791
(s, 1H, aromatic C2). Mass (m/z,%): 450(M+ 1.3), 373(8.4),
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134(2.6), 115(1.5) calculated for C25H27FN4O3: C, 66.66;




Yield 85% , m.p. 130°C, UV nm (ε): 212 (25790), 292
(16538), 325 (6058), 464 (14048), IR (KBr) νmax: 3387,
3208, 3063, 2971, 2863, 2382, 1610, 1510, 1469, 1283,
1220, 1138, 1075, 893 cm-1, 1H NMR (MeOD, 400 MHz)
δ: 0.96-0.98 & 1.08-1.20 (m, 4H cyclopropane), 2.89-3.40
(m, 10H, of piperazine ring), 3.75 (s, OCH3), 3.96-4.02
(m, 1H, cyclopropane), 5.68 (s, 1H, NH), 6.87-6.92 (m, 10H,
aromatic), 7.2 (s, MeOD), 7.8-7.87 (d, 1H, aromatic C5,
J =12), 8.75 (s, 1H, aromatic C2). Mass (m/z,%): 465(M+
1.39), 373(1.6), 319(100), 275(22.8), 219(5.8), 189(3.9),
147(2.0), 95(4.6), 76(5.0), 70(31), 56(13) calculated for
C25H28FN5O3: C, 64.51; H, 6.02; N, 15.05. Found: C,
64.50; H, 6.02; N, 15.1.
1-(1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-
1-yl)-4-oxo-1,4-dihydroquinoline-3-carbonyl)urea [8]
Yield 79% , m.p. 152°C, UV nm (ε): 213.5 (21102), 232
(21849), 293.5 (40328), 324.5 (14382), IR (KBr) νmax:
3440, 2978, 2862, 2480, 2382–2364, 1627, 1450, 1396,
1286, 1215, 1064, 1002.31, 829, 736 cm-1, 1H NMR
(MeOD, 400 MHz) δ: 0.94-0.98 & 1.11-1.20 (m, 4H
cyclopropane), 1.36-1.38 (d, 3H, J = 6.69), 1.97 (s, 1H, NH),
2.90-3.41 (m, 8H, of piperazine ring), 3.75 (s, OCH3),
3.96-4.03 (m, 1H, cyclopropane), 4.51 (s, 1H, NH), 7.24
(s, MeOD), 7.82-7.86 (d, 1H, aromatic C5, J =12), 8.78
(s, 1H, aromatic C2). Mass (m/z,%): 417(M+ 4.4), 362
(2.3), 319(51), 275(100), 221(3.5), 167(2.5), 137(14), 95
(6.64), 76(3) calculated for C20H24FN5O4: C, 57.55; H,




Yield 80% , m.p. 250°C, UV nm (ε): 228.5 (31597), 292.5
(37924), 325.5 (13728), IR (KBr) νmax: 3413, 3304, 2853,
1726, 1621.7, 1513.69, 1426.09, 1369.57, 1278, 1056,
1034, 926.6, 804, 760.8, 673.91 cm-1, 1H NMR (MeOD,
400 MHz) δ: 0.92-0.93 & 1.13-1.24 (m, 4H cyclopro-
pane), 1.25-1.27 (d, 3H, J = 8), 3.10-3.45 (m, 7H, of pi-
perazine ring), 3.66 (s, OCH3), 3.94-3.98 (m, 1H,
cyclopropane), 6.53-6.59 & 7.15-7.18 (m, 4H, aromatic)
7.2 (s, MeOD), 7.78-7.81 (d, 1H, aromatic C5), 8.74 (s, 1H,
aromatic C2). Mass (m/z,%): 494(M+ 0.59), 450(2), 373
(3.7), 319(58), 263(1.4), 233(1.5), 190(2.4), 137(72.8), 119
(100), 76(2.0) calculated for C26H27FN4O5: C, 63.15; H,
5.46; N, 11.33. Found: C, 63.12; H, 5.64; N, 11.30.5-Benzamido-1-cyclopropyl-6-fluoro-8-methoxy-7-
(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid [10]
Yield 69% , m.p. 92-93°C, UV nm (ε): 230 (26840), 293
(35577), 326 (12660), 693 (1228), IR (KBr) νmax: 3409,
3051, 2863, 2480, 2374, 1612, 1575, 1460–1446, 1392,-61,
1321, 1281, 1053.86, cm-1, 1H NMR (MeOD, 400 MHz)
δ: 0.96-0.98 & 1.09-1.23 (m, 4H cyclopropane), 1.57,
2.87-3.3 (m, 8H, of piperazine ring), 3.75 (s, OCH3),
3.97-4.02 (m, 1H, cyclopropane), 5.8-6.1 (bs, 1H, NH),
7.23 (s, MeOD), 7.41-7.51 & 7.77-7.89 (m, 5H, aromatic),
8.71 (s, 1H, aromatic C2). Mass (m/z,%): 478(M
+ 1.39), 373
(28), 319(100), 275(20), 219(5.2), 167(3.4), 125(3.4), 95(6.5),
76(3.68), 70(22), 56(18) calculated for C26H27FN4O4: C,




Yield 75% , m.p. 143°C, UV nm (ε): 208 (53093), 232
(66000), 283 (71517), IR (KBr) νmax: 3433, 2987, 2847,
2480, 2183, 1629, 1463, 1323, 1284, 1057, 1005, 940,
892, 826 cm-1, 1H NMR (MeOD, 400 MHz) δ: 0.91-0.96
& 1.14-1.19 (m, 4H cyclopropane), 1.37-1.38 (d, 3H, J =
5.42), 1.90 (s, 3H, C20), 3.19-3.54 (m, 7H, of piperazine
ring), 3.75 (s, OCH3), 3.94-3.99 (m, 1H, cyclopropane), 7.2
(s, MeOD), 7.61 (d, 1H, aromatic C5, J =12 ), 8.75 (s, 1H,
aromatic C2). Mass (m/z,%): 432(M+ 0.99), 376(8.38), 319
(100), 233(4.6), 179(68), 126(42), 96(24), 77(30), 70(20), 56
(24) calculated for C21H25FN4O3S: C, 58.33; H, 5.78; N,
12.96. Found: C, 58.31; H, 5.74; N, 12.94.
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-
4-oxo-N,N-diphenyl-1,4-dihydroquinoline-3-carboxamide [12]
Yield 89% , m.p. 132°C, UV nm (ε): 206 (50852), 290
(22344), IR (KBr) νmax: 3417, 3070, 2850, 2382–40, 1619,
1462, 1360, 1282, 1208, 1172, 1147, 1140, 1059, 995.71,
935.8 cm-1, 1H NMR (MeOD, 400 MHz) δ: 0.96-0.98 &
1.08-1.20 (m, 4H, cyclopropane), 2.89-3.40 (m, 10H, of
piperazine ring), 3.75 (s, OCH3), 3.96-4.02 (m, 1H, cyclopro-
pane), 5.68, 6.87-6.92 (m, 10H, aromatic), 7.23 (s, MeOD),
7.87 (d, 1H, J = 12), 8.78(s,1H). Mass (m/z,%): 526(M+
0.32), 428(2.8), 374(100), 344(36), 176(2.8) calculated
for C31H31FN4O3: C, 70.72; H, 5.89; N, 10.64. Found: C,
70.71; H, 5.83; N, 10.52.
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-
4-oxo-1,4-dihydroquinoline-3-carbohydrazide [13]
Yield 72% , m.p. 250°C, UV nm (ε): 212.5 (18321), 231.5
(17004), 293 (31039), 325 (11179), IR (KBr) νmax: 3445,
3155.9, 2951, 2871, 2497, 1623, 1516, 1467, 1250, 1104,
1059–1094, 944 cm-1, 1H NMR (MeOD, 400 MHz) δ:
0.95-1.19 (m, 4H cyclopropane), 1.43-1.45 (d, 3H, J = 8),
2.38 (s, 3H, NH), 3.20-3.76 (m, 7H, of piperazine ring),
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(s, MeOD), 7.83-7.87 (d, 1H, J = 12), 8.78 (s, 1H). Mass
(m/z,%): 489(M+ 11.2), 373(9.9), 319(100), 288(4.9), 259
(18.4), 244(3.7), 216(3.2), 188(2.5), 146(1.5), 92(1.2) cal-
culated for C19H24FN5O3: C, 58.60; H, 6.21; N, 17.98.
Found: C, 58.59; H, 6.17; N, 17.95.
1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-
4-oxo-N-phenyl-1,4-dihydroquinoline-3-carbohydrazide [14]
Yield 75% , m.p. 170°C, UV nm (ε): 213 (28942), 230
(27927), 291.5 (44364), 325.5 (17457), IR (KBr) νmax:
3433, 3083, 2849, 2483, 2383, 1621, 1522, 1468–47,
1060, 932 cm-1, 1H NMR (MeOD, 400 MHz) δ: 0.87-
1.39 (m, 4H cyclopropane), 1.46-1.48 (d, 3H, J = 8), 1.97
(s, 1H, NH), 2.40 & 3.00-3.39 (m, 7H, of piperazine
ring), 3.73 (s, OCH3), 3.95-4.01 (m, 1H, cyclopropane),
6.80-6.82 (m, 2H, aromatic C19,23), 6.89-6.91 (m, 1H,
aromatic C21), 7.24 (s, MeOD), 7.42-7.51 (m, 2H, aro-
matic C20,22), 7.50 (d, 1H, aromatic C5, J =12 ), 8.312
(s, 1H, C = N – NH -), 8.76 (s, 1H, aromatic C2). Mass
(m/z,%): 465.5(M+ 0.49), 388(1.07), 373(4.6), 319(100),
288(9.2), 259(28.1), 219(13.4), 188(5), 148(3), 92(5) cal-
culated for C25H28FN5O3: C, 64.50; H, 6.06; N, 15.04.




Yield 75% , m.p. 156°C, UV nm (ε): 211 (21855), 292
(28415), 325 (10129), IR (KBr) νmax: 3065, 2859, 2362,
1725, 1618, 1469–1458, 1319, 1273, 1209, 1059 cm-1,
1H NMR (MeOD, 400 MHz) δ: 0.889-0.931 & 1.01-1.03
(m, 4H of cyclopropane, 1.12-1.14(d, 3H of CH3 of pi-
perazine ring, J = 8), 2.79-3.34 (m, 8H of piperazine),
3.68 (s, 3H, OCH3), 3.94-3.97 (m, 1H, of cyclopropane),
6.70-6.75 (m, 4H aromatic), 7.07-7.11 (m, 4H, aromatic),
7.07-7.11 (t, 1H, aromatic J = 7.88), 7.23 (s, MeOD), 7.73-
7.76 (d, 1H aromatic, J = 12), 8.70 (s, 1H). Mass (m/z,%):
451(M+ 0.97), 395(1.6), 365(27.69), 351(6.22), 323(100),
230(3.39), 176(2.76), 70(10.43), 56(10.20) calculated for
C25H26FN3O4: C, 66.51; H, 5.80; N, 9.31. Found: C, 66.31;




Yield 73% , m.p. 140-142°C, UV nm (ε): 214 (21338),
231 (21410), 292 (39853), 325 (14058), IR (KBr) νmax:
3443, 3034, 2834, 1721, 1600, 1569.57, 1465.22, 1365.22,
1260.87, 1169, 1134, 1034, cm-1, 1H NMR (MeOD,
400 MHz) δ: 0.897- 0.937 & 1.13-1.14 (m, 4H, cyclopro-
pane), 1.31-1.33 (d, 1H, J = 8, CH3 of piperazine), 2.991
(s, 3H, NH), 3.01-3.15 (m, 7H of piperazine), 3.69 (s, 1H,
OCH3), 3.93-3.98 (m, 1H, cyclopropane), 6.10-6.16(m, 2H aromatic, C19-21), 6.83 (m, 1H, aromatic C17), 7.01
(t, 1H, C18), 7.23 (MeOD), 7.57 (d, 1H, J = 12), 8.71
(s, 1H). Mass (m/z,%): 466(M+ 0.49), 374(3.34), 319
(100), 275(11.7), 219(5.84), 166(3.28), 136(3.19), 70
(43), 56(27.47) calculated for C25H27FN4O4: C, 64.37;




Yield 79%, m.p. 165°C, UV nm (ε): 213 (22304), 232
(22727), 293.5 (41090), 324 (14722). IR (KBr) νmax:
3424–3319, 3013.19, 2856, 1725.21, 1629, 1537–1515,
1450.431, 1376, 1315–1254, 1057 cm-1, 1H NMR
(MeOD, 400 MHz) δ: 0.94-1.23 (m, 4H cyclopropane),
2.89 (s, 3H, NH), 2.92-3.4 (m, 7H, of piperazine ring),
3.74 (s, OCH3), 3.97-4.02 (m, 1H, cyclopropane), 6.73
(m, 4H aromatic), 7.83-7.87 (d, 1H, J = 16), 8.79 (s, 1H).
Mass (m/z,%): 466(M+ 1.2), 374(21.3), 319(100), 275
(27.06), 219(3.3), 166(3.6), 136(7), 95(25.25), 70(41.5), 56
(51.9) calculated for C25H27FN4O4: C, 64.37; H, 5.83; N,




Yield 70%, m.p. 165.5°C, UV nm (ε): 214 (26267), 292
(32648), 325 (11685).. IR (KBr) νmax: 3428, 2990, 2841,
2742, 2344, 1735, 1619, 1577, 1543, 1460, 1450, 1395,
1365, 1280, 1215, 1180, 1143, 1065–1058, 998, 938 cm-1,
1H NMR (MeOD, 400 MHz) δ: 0.90-0.94 & 1.12-1.18
(m, 4H of cyclopropane, 1.372-1.389(d, 3H of CH3 of pi-
perazine ring, J = 6.8), 3.02-3.44 (m, 8H of piperazine),
3.70 (s, 3H, OCH3), 3.94-3.99 (m, 1H, of cyclopropane ),
6.21-6.26 (t, 1H aromatic, C20 J = 16 ), 7.2 (s, MeOD),
7.80-7.77 (d, 1H, aromatic J = 12), 8.73 (s, 1H). Mass
(m/z,%): 467(M+ 0.3), 374(25.93), 319(100), 275(13.9),
219(6.08), 70(44), 56(39.5) calculated for C25H26FN3O5:





Yield 72%, m.p. 75-80°C, UV nm (ε): 207 (31605), 292
(24701). IR (KBr) νmax: 3433, 2978, 2935, 2873, 2402,
1733–1723, 1621, 1455, 1438, 1276, 1122, 1070 cm-1, 1H
NMR (MeOD, 400 MHz) δ: 0.76-0.91 & 1.14-1.36 (m, 4H of
cyclopropane, 1.47(d, 3H of CH3 of piperazine ring, J = 8),
3.24-3.45 (m, 8H of piperazine), 3.62 (s, 3H, OCH3),
4.05-4.14 (m, 1H, of cyclopropane ), 6.15 (d, 2H aromatic,
J = 9.04 ), 6.37 (t, 2H, J = 16), 7.23 (s, MeOD), 7.31 (s, 2H,
OH), 7.76 (d, 1H, aromatic J = 12), 8.73 (s, 1H). Mass (m/z,%):
483(M+ 0.59), 374(1.9), 319(100), 275(16.18), 219(2.8),
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Yield 78%, m.p. 82°C, UV nm (ε): 214 (26358), 292
(31965), 325 (10685). IR (KBr) νmax: 3250, 2991, 2856,
1709, 1695, 1565, 1513, 1491, 1382, 1278.26, 1182.6,
1104 cm-1, 1H NMR (MeOD, 400 MHz) δ: 0.90-0.94 &
1.12-1.18 (m, 4H of cyclopropane, 1.372-1.389(d, 3H of
CH3 of piperazine ring, J = 6.8), 3.02-3.44 (m, 8H of pi-
perazine), 3.70 (s, 3H, OCH3), 3.94-3.99 (m, 1H, of
cyclopropane ), 6.21-6.26 (t, 1H aromatic, C20 J = 16 ),
7.2 (s, MeOD), 7.80-7.77 (d, 1H, aromatic J = 12), 8.73
(s, 1H). Mass (m/z,%): 467(M+ 3.3), 374(38), 319(100),
275(4.6), 219(2.8), 189(5.6), 147(9.1), 95(3), 76(34), 70
(28), 56(50) calculated for C25H26FN3O5: C, 64.23; H,
5.61; N, 8.99. Found: C, 64.19; H, 5.60; N, 8.98.
Biological studies
Phagocyte chemiluminescence
Preparation of opsonized zymosan and luminol
The opsonization of zymosan particles was carried out
following Wick’s method [24] with some modifications.
Briefly, zymosan (100 mg) was mixed in 5 mL phosphate
buffer saline (PBS) pH 7.4 and 5 ml fresh-pooled serum
from healthy human volunteers. The mixture was incu-
bated at 37°C in a shaking water bath for 30 min, then cen-
trifuged, washed twice with PBS and finally re-suspended
in 5 ml of PBS. The mixture was stored at −20° C till use
and was brought to room temperature immediately before
experiment. Luminol solution (7 × 10-5 M) was prepared
by dissolving 1.8 mg of luminol in 1 mL borate buffer
pH 9.1 and vortexed for 5–10 min. The solution was then
further diluted up to 10 mL with Hanks balanced salt solu-
tion HBSS++ (containing Ca and Mg), to give 180 μg mL-1.
Isolation of polymorphoneutrophils (PMNs) and mouse
peritoneal macrophages
The heparinized human whole blood was diluted with
Hanks balanced salt solution (HBSS–) and mixed with
one third of dextrin (3% in 0.9% NaCl) solution for dif-
ferential sedimentation and removal of erythrocytes.
After gentle mixing, it was kept at room temperature for
20 min undisturbed. The upper layer containing leuco-
cytes was collected and gently layered over an equal vol-
ume of lymphocytes separation medium (LSM) and then
subjected to centrifugation at 400 g for 25 min at room
temperature. After removal of the upper phase, neutro-
phils were collected and subjected to hypotonic lysis of
RBC with sterile distilled water for one minute, and then
washed twice with HBSS–. Macrophages from mouseperitoneal cavity were obtained as described in our pre-
vious paper [23]. Cells were re-suspended in HBSS– to
give 1 × 106 /mL.
Chemiluminescence assay
The assay was performed as described by Helfand et al.,
[25] protocol. Briefly gatifloxacin and the other deriva-
tized compounds were diluted in three different concen-
trations in HBSS++ containing calcium and magnesium.
25 μL of either diluted blood (1:50 dilution in sterile
PBS, pH 7.4) or polymorphoneutrophils (1 x 106 mL-1)
or mouse peritoneal macrophages (1 × 106 mL-1) were
added to the culture reaction. After 15 minutes of incu-
bation for whole blood and 30 minutes for isolated cells,
25 μL (7 × 10-5 M) luminol, followed by 25 μL
(20 mg mL-1) serum opsonized zymosan-A. HBSS++
alone without compounds was run as negative control.
The level of reactive oxygen species (ROS) after incuba-
tion with compounds was monitored for 50 minutes by
the Luminometer. The total ROS level was recorded as
total light produced and recorded during the 50 minutes
scan. The total integral chemiluminescence reading was
expressed in the relatively light unit (RLU).
T-cell proliferation assay
In vitro cell proliferation assay was carried out using H3
thymidine incorporation method based on technique of
Nielsen et al., [26] in a sterile environment. Peripheral
blood mononuclear cells (PBMC) were isolated from
heparinized venous blood of healthy human by Ficoll-
Hypaque gradient centrifugation. These cells cultured in
a 96 well round bottom plate at concentration of 2 x 106
cells mL-1 in RPMI-1640 media supplemented with 5%
FBS in presence of compounds and Phytohemagglutinin
(PHA) with concentration of 5 μg mL-1. The concentra-
tions of compounds were 3.1, 12.5 and 50 μg mL-1, each
used in triplicate. The plate was incubated at 37°C for
72 hrs in 5% CO2 incubator with the final volume of
0.2 mL per well. After 72 hrs, 25 μl of H3 thymidine was
(0.5μci/well) added to the culture plate incubated for
further 18 hrs. Cells were harvested on a glass fiber filter
using cell harvester system. Effect of compounds on pro-
liferation of cells was measured quantitatively by liquid
β-Scintillation Counter. Results were recorded as count
per minute (CPM). Inhibitory effect of compounds was
calculated in comparison to the control.
Toxicity on T cells
The toxicity of compounds showing inhibitory effect
on T cells was also analyzed using same procedure of T
cell proliferation. Cells were cultured in presence of
compounds for 24 hrs and after one day compounds
were removed by washing cells before addition of the
PHA (5 μg/mg mL-1) for 72 hrs. After 72 hrs, 25 μl of
Sultana et al. Chemistry Central Journal 2013, 7:6 Page 11 of 11
http://www.journal.chemistrycentral.com/content/7/1/6radioactive H3 thymidine was added to each well in the
plate for further 18 hrs. Results were recorded as count
per minute (CPM) using the liquid scintillation counter.
Conclusion
Seventeen derivatives of gatifloxacin were synthesized,
characterized and tested for immunomodulatory activ-
ities in phagocyte chemiluminescence and T-Cell prolif-
eration assay. The anti-inflammatory mechanism was
elucidated, which provided valuable information for fur-
ther studies on the novel anti-inflammatory quinolones.
The most active quinolone compounds had IC50 values
< 3.1 μg mL-1, while several derivatives were not active
at a concentration of 100 μg mL-1. In SAR studies, the
data suggested that C-3 of quinolone ring with exocyclic
substituted phenylenamine ring influenced the immuno-
modulatory activities. In particular, p-phenylendiamine
substituted analog 7 and m-aminophenol substituted
analogue 16 exhibited highly suppressive oxidative burst
activity of neutrophils, macrophages and phagocytes
with significant antibacterial activity compared to that of
gatifloxacin. These studies also demonstrated that exo-
cyclic phenyl ring suitably substituted with hydroxyl,
amino or hydrazide group envision potent inhibitory effect
on cell immediate immunity as compared to humoral im-
munity with reduced cytotoxic effect especially phenylhy-
drazide and phenyl hydroxyl analogs. Currently the
intensive studies on compounds 7, 16, 14 and 20 includ-
ing the detailed structure activity relationship and the
anti-inflammatory mechanism are in progress.
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